FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922082948> ?p ?o ?g. }

• W2922082948 abstract "We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year. Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0. Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], − 1.43; 95% confidence interval [CI], − 2.20 to − 0.66; P = 0.0003), prostate volume (MD, − 10.13; 95% CI, − 12.38 to − 7.88; P < 0.00001), transitional zone volume (MD, − 3.18; 95% CI, − 3.57 to − 2.79; P<0.0001), maximum urine flow rate (MD, 1.05; 95% CI, 0.82 to 1.29; P < 0.00001), prostate specific antigen (MD, − 0.54; 95% CI, − 0.80 to − 0.29; P < 0.0001) and post-void residual volume (MD, − 3.85; 95% CI, − 4.95 to − 2.76; P < 0.00001) compared with the tamsulosin group. In terms of safety, including adverse events (odds ratio [OR], 2.06; 95% CI, 1.34 to 3.17; P = 0.001), erectile dysfunction (OR, 2.24; 95% CI, 1.73 to 2.92; P < 0.00001), ejaculation disorder (OR, 3.37; 95% CI, 1.97 to 5.79; P < 0.0001), retrograde ejaculation (OR, 2.30; 95% CI, 1.08 to 4.93; P = 0.03), decreased libido (OR, 2.25; 95% CI, 1.53 to 3.31; P < 0.0001) and loss of libido (OR, 3.38; 95% CI, 1.94 to 5.88; P<0.0001), the combination group showed poor tolerance than the tamsulosin group with the exception of dizziness (OR, 1.16; 95% CI, 0.75 to 1.80; P = 0.50). The combination group significantly reduced the risk of clinical progression than the tamsulosin group especially in incidence of BPH-related symptom progression (OR, 0.56; 95% CI, 0.46 to 0.67; P < 0.00001) and acute urinary retention (OR, 0.61; 95% CI, 0.38 to 0.98; P = 0.04). The combination of tamsulosin plus dutasteride provides a preferable therapeutic effect for BPH with a higher incidence of sexual side effects, but combination-therapy can markedly reduce risk of BPH-related symptom progression and acute urinary retention relative to tamsulosin monotherapy." @default.
• W2922082948 created "2019-03-22" @default.
• W2922082948 creator A5032776730 @default.
• W2922082948 creator A5043354088 @default.
• W2922082948 creator A5046189089 @default.
• W2922082948 creator A5055795347 @default.
• W2922082948 creator A5067285741 @default.
• W2922082948 date "2019-03-11" @default.
• W2922082948 modified "2023-09-28" @default.
• W2922082948 title "Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia" @default.
• W2922082948 cites W1520748992 @default.
• W2922082948 cites W1925520630 @default.
• W2922082948 cites W1966319592 @default.
• W2922082948 cites W1970782054 @default.
• W2922082948 cites W2005501262 @default.
• W2922082948 cites W2013120447 @default.
• W2922082948 cites W2018377518 @default.
• W2922082948 cites W2044216158 @default.
• W2922082948 cites W2051592657 @default.
• W2922082948 cites W2058378922 @default.
• W2922082948 cites W2058677706 @default.
• W2922082948 cites W2088567034 @default.
• W2922082948 cites W2091348312 @default.
• W2922082948 cites W2092070631 @default.
• W2922082948 cites W2092885298 @default.
• W2922082948 cites W2101568123 @default.
• W2922082948 cites W2107328434 @default.
• W2922082948 cites W2126104986 @default.
• W2922082948 cites W2130782215 @default.
• W2922082948 cites W2144490947 @default.
• W2922082948 cites W2252804958 @default.
• W2922082948 cites W2291415130 @default.
• W2922082948 cites W2397870557 @default.
• W2922082948 cites W2409752089 @default.
• W2922082948 cites W2509819831 @default.
• W2922082948 cites W2576597202 @default.
• W2922082948 cites W2584084000 @default.
• W2922082948 cites W2593339698 @default.
• W2922082948 cites W2660683196 @default.
• W2922082948 cites W2766742055 @default.
• W2922082948 cites W2979020615 @default.
• W2922082948 cites W2982353019 @default.
• W2922082948 cites W3191350591 @default.
• W2922082948 cites W4236163484 @default.
• W2922082948 doi "https://doi.org/10.1186/s12894-019-0446-8" @default.
• W2922082948 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6419503" @default.
• W2922082948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30871552" @default.
• W2922082948 hasPublicationYear "2019" @default.
• W2922082948 type Work @default.
• W2922082948 sameAs 2922082948 @default.
• W2922082948 citedByCount "19" @default.
• W2922082948 countsByYear W29220829482020 @default.
• W2922082948 countsByYear W29220829482021 @default.
• W2922082948 countsByYear W29220829482022 @default.
• W2922082948 countsByYear W29220829482023 @default.
• W2922082948 crossrefType "journal-article" @default.
• W2922082948 hasAuthorship W2922082948A5032776730 @default.
• W2922082948 hasAuthorship W2922082948A5043354088 @default.
• W2922082948 hasAuthorship W2922082948A5046189089 @default.
• W2922082948 hasAuthorship W2922082948A5055795347 @default.
• W2922082948 hasAuthorship W2922082948A5067285741 @default.
• W2922082948 hasBestOaLocation W29220829481 @default.
• W2922082948 hasConcept C121608353 @default.
• W2922082948 hasConcept C126322002 @default.
• W2922082948 hasConcept C126894567 @default.
• W2922082948 hasConcept C156957248 @default.
• W2922082948 hasConcept C168563851 @default.
• W2922082948 hasConcept C197934379 @default.
• W2922082948 hasConcept C2776235491 @default.
• W2922082948 hasConcept C2776547966 @default.
• W2922082948 hasConcept C2777562237 @default.
• W2922082948 hasConcept C2778878792 @default.
• W2922082948 hasConcept C2779478474 @default.
• W2922082948 hasConcept C2780542891 @default.
• W2922082948 hasConcept C44249647 @default.
• W2922082948 hasConcept C71924100 @default.
• W2922082948 hasConcept C95190672 @default.
• W2922082948 hasConceptScore W2922082948C121608353 @default.
• W2922082948 hasConceptScore W2922082948C126322002 @default.
• W2922082948 hasConceptScore W2922082948C126894567 @default.
• W2922082948 hasConceptScore W2922082948C156957248 @default.
• W2922082948 hasConceptScore W2922082948C168563851 @default.
• W2922082948 hasConceptScore W2922082948C197934379 @default.
• W2922082948 hasConceptScore W2922082948C2776235491 @default.
• W2922082948 hasConceptScore W2922082948C2776547966 @default.
• W2922082948 hasConceptScore W2922082948C2777562237 @default.
• W2922082948 hasConceptScore W2922082948C2778878792 @default.
• W2922082948 hasConceptScore W2922082948C2779478474 @default.
• W2922082948 hasConceptScore W2922082948C2780542891 @default.
• W2922082948 hasConceptScore W2922082948C44249647 @default.
• W2922082948 hasConceptScore W2922082948C71924100 @default.
• W2922082948 hasConceptScore W2922082948C95190672 @default.
• W2922082948 hasIssue "1" @default.
• W2922082948 hasLocation W29220829481 @default.
• W2922082948 hasLocation W29220829482 @default.
• W2922082948 hasLocation W29220829483 @default.
• W2922082948 hasLocation W29220829484 @default.
• W2922082948 hasOpenAccess W2922082948 @default.
• W2922082948 hasPrimaryLocation W29220829481 @default.
• W2922082948 hasRelatedWork W1580447354 @default.

• next